Share “Elan, Biogen change terms of Tysabri...”

Elan, Biogen change terms of Tysabri collaboration

Published on NewsOK Modified: February 6, 2013 at 5:00 pm •  Published: February 6, 2013

Tysabri was considered a breakthrough because it stopped MS relapses 70 percent of the time while removing lingering traces of symptoms. However, it was briefly yanked the market in 2005 when some patients with a common background virus developed brain infections.

In a rare move, the Food and Drug Administration allowed Tysabri back on the market in 2006 with strict protocols. Patients are tested for the virus, must come in for the IV treatment every four weeks and must check in with their neurologist every three months.

The companies said in the fall about 71,000 patients were being treated with Tysabri in 2012. That was up 13 percent from a year ago.

Biogen shares rose $3.62, or 2.3 percent, to $160.98 in trading Wednesday after rising as high as $167.35 earlier in the session. That was an all-time high, according to FactSet.